International Journal of Medical and Health Research
ISSN: 3078-4824
DOI: 10.61424/ijmhr
Journal Homepage: www.bluemarkpublishers.com/index.php/IJMHR

IJMHR
BLUEMARK PUBLISHERS

| RESEARCH ARTICLE

A Data-Driven Epidemiological Approach to Preventing Opioid Overdose Escalation in U.S. Communities: Integrating Predictive Analytics, Geospatial Modeling, and Community Intervention

Sandra Gyamfuaa Badu
Department: Epidemiology and Community Health, Health informatics, University of North Carolina at Charlotte, USA
Corresponding Author: Sandra Gyamfuaa Badu, **E-mail**: sandrabadu@rocketmail.com

| ABSTRACT
The opioid epidemic represents one of the most severe public health crises facing the United States in the 21st century. Despite substantial intervention efforts over the past two decades, opioid-related mortality continues to exact devastating tolls on American communities, with approximately 79,358 opioid-involved deaths occurring in 2023 alone. This research presents a comprehensive epidemiological framework that integrates advanced predictive analytics, machine learning methodologies, geospatial analysis, and community-based interventions to proactively identify and prevent opioid overdose escalation before crisis levels are reached. Through systematic analysis of multi-source data including mortality statistics, prescription monitoring programs, emergency department encounters, and sociodemographic determinants, this study develops a hybrid predictive-intervention model capable of forecasting opioid overdose risks at granular geographic scales. The proposed framework encompasses four integrated components: a predictive risk modeling system utilizing machine learning algorithms, a community-driven intervention toolkit tailored to forecasted risks, an early warning dashboard for real-time visualization, and evidence-based harm reduction strategies. By synthesizing epidemiological surveillance with computational modeling and community engagement, this approach represents a paradigm shift from reactive crisis response toward proactive prevention, offering actionable pathways for reducing opioid-related morbidity and mortality across diverse community contexts.

| KEYWORDS
Opioid epidemic, predictive modeling, geospatial analysis, harm reduction, public health intervention, machine learning, epidemiology.

| ARTICLE INFORMATION
ACCEPTED: 12 May 2025 **PUBLISHED:** 17 August 2025 **DOI:** 10.61424/ijmhr.v3.i3.490

1. Introduction
The opioid crisis has fundamentally reshaped the landscape of public health in the United States, creating what the Centers for Disease Control and Prevention has characterized as a multi-wave epidemic with evolving characteristics and escalating severity (Spencer et al., 2024). From 1999 through 2023, approximately 806,000 Americans died from opioid-related overdoses, representing a mortality toll that exceeds U.S. combat deaths in all wars since World War II combined (National Center for Health Statistics, 2024). The crisis has progressed through three distinct waves, beginning with increased prescription opioid deaths in the 1990s, transitioning to heroin-related fatalities in 2010, and subsequently dominated by synthetic opioids, particularly illicitly manufactured fentanyl and fentanyl analogs, since 2013 (Volkow & Blanco, 2021).

Recent epidemiological data reveals the magnitude and evolving nature of this public health emergency. In 2023, approximately 105,007 drug overdose deaths occurred in the United States, with 79,358 involving opioids, accounting for approximately 76% of all overdose fatalities (Spencer et al., 2024). While provisional data from 2024 suggests a decline of approximately 24% in overdose deaths compared to the previous year, this represents the first sustained decrease since 2018, and significant geographic and demographic disparities persist (CDC, 2025). Synthetic opioids other than methadone, primarily fentanyl, accounted for 72,776 deaths in 2023, and polysubstance overdoses involving both opioids and stimulants now constitute 47% of drug overdose deaths in jurisdictions with complete reporting (National Institute on Drug Abuse, 2025).

The economic burden of the opioid crisis extends far beyond mortality statistics, encompassing healthcare costs, criminal justice expenditures, lost productivity, and diminished quality of life for individuals, families, and communities. Conservative estimates place the economic impact at over $1 trillion annually when accounting for direct and indirect costs (Florence et al., 2016). Traditional public health responses, while valuable, have predominantly operated in reactive modes, responding to overdose events rather than preventing them through predictive intervention strategies.

Contemporary surveillance systems, including Prescription Drug Monitoring Programs (PDMPs) and the National Syndromic Surveillance Program, provide critical data infrastructure for understanding opioid-related harms. However, these systems face substantial limitations in their ability to forecast emerging hotspots and guide preemptive resource allocation (Puac-Polanco et al., 2020). The integration of advanced computational methods, including machine learning algorithms and geospatial analytics, offers unprecedented opportunities to transform epidemiological surveillance from descriptive to predictive paradigms (Lo-Ciganic et al., 2019).

This research addresses fundamental gaps in current approaches by developing an integrated framework that combines epidemiological rigor with computational innovation and community engagement. The objectives are threefold: first, to synthesize multi-source data streams into comprehensive risk profiles at community and individual levels; second, to develop and validate predictive models capable of identifying emerging overdose hotspots with sufficient lead time for intervention; and third, to design actionable intervention toolkits that translate predictions into evidence-based prevention strategies tailored to local contexts and resources.

2. Literature Review and Theoretical Framework

2.1 Epidemiology of the Opioid Crisis

The contemporary opioid epidemic emerged from complex interactions among pharmaceutical marketing practices, pain management paradigms, regulatory environments, and deeper socioeconomic determinants of health (Dasgupta et al., 2018). The first wave, beginning in the late 1990s, coincided with aggressive marketing of prescription opioids, including OxyContin, coupled with evolving pain management standards that positioned pain as the "fifth vital sign" (Van Zee, 2009). Prescription opioid deaths increased from 3,442 in 1999 to a peak of 17,029 in 2017, though this represented only one component of an increasingly complex crisis (National Institute on Drug Abuse, 2025).

The second wave emerged around 2010 as heroin-related deaths escalated rapidly, partly reflecting substitution effects as prescription opioid access became more restricted through regulatory interventions. Heroin deaths rose from 3,036 in 2010 to 15,469 in 2016 before declining to 3,984 in 2023 (Spencer et al., 2024). However, even as heroin deaths decreased in absolute numbers, the proportion involving co-occurring synthetic opioids increased to approximately 80% by 2023, illustrating the crisis's evolutionary nature.

The third and most lethal wave began around 2013 with the proliferation of illicitly manufactured fentanyl and its analogs. Fentanyl, approximately 50 times more potent than heroin, became increasingly prevalent in illegal drug markets, often adulterated into counterfeit prescription pills, heroin, cocaine, and methamphetamine without user awareness (Ciccarone, 2021). Synthetic opioid deaths increased from 3,105 in 2013 to 73,838 in 2022, representing a more than 20-fold increase (National Institute on Drug Abuse, 2025). The ubiquity of fentanyl in the illicit drug supply fundamentally altered overdose risk profiles, as even individuals not intentionally seeking opioids faced exposure.

Table 1: Three Waves of the U.S. Opioid Epidemic

Wave	Time Period	Primary Opioid Type	Peak Deaths (Year)	Key Drivers
First Wave	1990s-2010	Prescription opioids (oxycodone, hydrocodone)	17,029 (2017)	Aggressive pharmaceutical marketing; pain management paradigm shifts; liberal prescribing patterns
Second Wave	2010-2013	Heroin	15,469 (2016)	Prescription restrictions, lower cost, and greater accessibility of heroin; existing opioid dependence
Third Wave	2013-Present	Synthetic opioids (fentanyl, analogs)	73,838 (2022)	Illicit manufacturing; drug supply adulteration; extremely high potency; polysubstance use patterns

Source: Compiled from National Institute on Drug Abuse (2025); Spencer et al. (2024); Volkow & Blanco (2021)

2.2 Sociodemographic and Environmental Determinants

Opioid-related mortality exhibits profound disparities across demographic groups and geographic regions, reflecting complex interactions among individual vulnerabilities, social determinants of health, and structural inequities. Recent evidence demonstrates widening racial and ethnic disparities, contradicting earlier characterizations of the opioid crisis as predominantly affecting non-Hispanic white populations (Kariisa et al., 2022).

From 2019 to 2020, drug overdose death rates increased 44% among non-Hispanic Black individuals and 39% among American Indian/Alaska Native populations, compared to 22% among non-Hispanic white individuals (Kariisa et al., 2022). By 2023, death rates stood at 48.9 per 100,000 for non-Hispanic Black individuals and 65.0 per 100,000 for American Indian/Alaska Native populations, compared to 46.6 per 100,000 for non-Hispanic white individuals (Spencer et al., 2024). These disparities appear driven not by differential substance use patterns but by inequitable access to evidence-based treatment, harm reduction services, and the social determinants of health (Saloner et al., 2020).

Geographic analyses reveal that opioid mortality clusters in specific regions characterized by economic distress, deindustrialization, and limited healthcare infrastructure. Counties with higher income inequality demonstrated elevated overdose death rates, particularly for Black and American Indian/Alaska Native populations (Kariisa et al., 2022). Rural communities face distinct challenges, including geographic isolation, limited treatment capacity, and provider shortages, yet recent years have witnessed increasing urban overdose rates as fentanyl proliferation extends across all community types (Hedegaard et al., 2023).

Individual-level risk factors identified through large-scale epidemiological studies include disability status (hazard ratio 2.80), male sex (hazard ratio 1.61), unemployment, housing instability, and prior incarceration (Singh et al., 2020). However, focusing exclusively on individual risk factors without addressing upstream social determinants perpetuates stigma and diverts attention from structural interventions that could prevent substance use disorders from developing (Dasgupta et al., 2018).

Table 2: Opioid Overdose Death Rates by Race/Ethnicity, 2020-2023

Race/Ethnicity	2020 Rate (per 100,000)	2023 Rate (per 100,000)	Percent Change	Risk Ratio (vs. Hispanic)
Non-Hispanic White	38.4	46.6	+21.4%	2.04
Non-Hispanic Black	34.0	48.9	+43.8%	2.14
American Indian/Alaska Native	46.9	65.0	+38.6%	2.85
Hispanic	18.2	22.8	+25.3%	1.00 (reference)
Asian/Pacific Islander	4.1	5.8	+41.5%	0.25

Source: Spencer et al. (2024); Kariisa et al. (2022); National Center for Health Statistics (2024). Note: Rates are age-adjusted per 100,000 standard population

2.3 Prescription Drug Monitoring Programs

Prescription Drug Monitoring Programs represent one of the most widely implemented policy interventions to address the opioid crisis. As of 2024, all 50 states and the District of Columbia operate PDMPs, which are electronic databases tracking controlled substance prescriptions (CDC, 2024). These systems aim to reduce inappropriate prescribing, identify doctor shopping behaviors, and inform clinical decision-making at the point of care.

Evidence regarding PDMP effectiveness presents a nuanced picture. Multiple systematic reviews demonstrate that PDMPs consistently reduce opioid prescribing volumes and quantities, with studies reporting decreases of 30% or more in Schedule II opioid prescribing following implementation (Bao et al., 2016). Among Medicare beneficiaries, PDMP implementation associated with reduced opioid volumes of 2.36 kg per month, with particularly strong effects among disabled beneficiaries (Moyo et al., 2017).

However, the relationship between reduced prescribing and improved health outcomes remains complex. Some studies found no association between PDMP implementation and overdose mortality reduction, while others documented potential substitution effects wherein restrictions on prescription opioids led to increased heroin use and related deaths (Dowell et al., 2017). A systematic review examining 22 studies across 49 PDMPs found limited evidence for overall effectiveness in reducing opioid-related harms and consequences, though PDMPs consistently reduced prescribing behaviors (Pardo, 2017).

Program characteristics significantly influence effectiveness. PDMPs with mandatory provider use requirements, real-time data updates, and integration with electronic health records demonstrate stronger associations with desired outcomes compared to voluntary systems with data lags (Haffajee et al., 2018). Interstate data sharing, clinical decision support tools, and proactive reporting to prescribers enhance utility. Nevertheless, PDMPs represent necessary but insufficient components of comprehensive responses, requiring integration with expanded treatment access, harm reduction services, and interventions addressing social determinants (Finley et al., 2017).

2.4 Machine Learning and Predictive Analytics

Recent advances in computational methods offer transformative potential for opioid epidemic response through improved risk stratification, early warning systems, and resource optimization. Machine learning approaches can identify complex patterns in high-dimensional data that traditional statistical methods may miss, potentially enabling more accurate prediction of individual and community-level overdose risk (Hastie et al., 2009).

Studies applying machine learning to opioid overdose prediction have demonstrated promising results across multiple settings and populations. Lo-Ciganic et al. (2019) developed algorithms predicting 3-month overdose risk among Medicare beneficiaries using pharmaceutical and healthcare claims data, achieving C-statistics of 0.84 in internal validation and 0.83 in external validation. Their Random Forest and gradient boosting models significantly outperformed traditional logistic regression, with the highest-risk decile capturing 63% of overdoses despite comprising only 10% of the population.

External validation studies examining algorithm transportability across states and time periods yield encouraging findings. A machine learning algorithm developed using Pennsylvania Medicaid data (2013-2016) maintained robust predictive performance when validated on more recent Pennsylvania data (2017-2018; C-statistic 0.828) and Arizona Medicaid data (2015-2017; C-statistic 0.817), demonstrating generalizability across heterogeneous populations and evolving epidemic contexts (Lo-Ciganic et al., 2022).

Table 3: Performance Metrics of Machine Learning Models for Opioid Overdose Prediction

Study	Population	Algorithm Type	C-statistic/AUC	Sensitivity	Specificity	Key Predictors
Lo-Ciganic et al. (2019)	Medicare beneficiaries	Random Forest	0.84	0.63	0.90	Prior overdose, substance use disorders, mental health diagnoses, high-dose opioids
Lo-Ciganic et al. (2022)	Medicaid beneficiaries	Gradient Boosting	0.82-0.84	0.55-0.73	0.88-0.91	Behavioral health conditions, pharmacy shopping, ED visits
Che et al. (2020)	Electronic health records	Deep Neural Network	0.90	0.86	0.95	Clinical events, vital signs, diagnosis codes, medications
Schell et al. (2021)	Community-level (census blocks)	XGBoost	0.73	N/A	N/A	Poverty, prescription rates, treatment access, income levels

Source: Compiled from Lo-Ciganic et al. (2019, 2022); Che et al. (2020); Schell et al. (2021). Note: C-statistic and AUC (Area Under the Curve) are equivalent measures of discriminative ability

At community levels, geospatial machine learning approaches identify neighborhood-level risk factors and predict geographic hotspots. Schell et al. (2021) used ensemble methods, including XGBoost and geographically weighted regression, to predict drug overdose at census block group levels in Rhode Island, achieving an R^2 of 0.73. Among sociodemographic factors, households receiving food assistance and annual incomes below $35,000 emerged as the strongest predictors, while opioid prescription rates and limited treatment access demonstrated significant associations.

Bayesian spatiotemporal models offer particular promise for small-area forecasting. Green et al. (2023) developed dynamic models predicting opioid mortality at ZIP Code Tabulation Area levels in Massachusetts, demonstrating superior performance for models incorporating full spatial and temporal dependencies. These models facilitated predictions two years forward, enabling preemptive public health planning and resource allocation to emerging hotspot areas before mortality escalations materialized.

Despite these advances, important limitations temper enthusiasm. Most studies rely on healthcare claims data, missing individuals without insurance coverage or those not accessing formal healthcare systems. Prediction models require regular updating as epidemic characteristics evolve. Privacy concerns and ethical considerations regarding potentially stigmatizing predictions necessitate careful governance frameworks. Model interpretability remains challenging with complex algorithms, potentially limiting clinical and public health utility. Furthermore, prediction alone provides insufficient value without integrated intervention systems capable of acting on forecasts.

2.5 Evidence-Based Interventions

Effective responses to opioid use disorder and overdose risk require comprehensive strategies spanning prevention, treatment, harm reduction, and recovery support. Medication for opioid use disorder represents the most evidence-based intervention for individuals with opioid dependence, with three FDA-approved options: methadone, buprenorphine, and extended-release naltrexone.

Methadone, a full mu-opioid receptor agonist, has demonstrated efficacy over more than 50 years of use. Randomized controlled trials show methadone reduces illicit opioid use by 33% and increases treatment retention compared to no medication, with associated reductions in infectious disease transmission, criminal justice involvement, and mortality (Mattick et al., 2014). However, methadone requires daily or near-daily visits to specialized opioid treatment programs, limiting accessibility in many communities.

Buprenorphine, a partial mu-opioid agonist combined with naloxone in most formulations, offers comparable efficacy with enhanced safety profiles due to ceiling effects limiting respiratory depression. Large-scale comparative effectiveness studies demonstrate that both medications significantly reduce opioid use, with methadone showing superior retention (74% vs 46% at 24 weeks) but buprenorphine demonstrating lower illicit use among those remaining in treatment (Hser et al., 2014). Critical advantages include office-based prescribing authority extended to physicians, nurse practitioners, and physician assistants, facilitating integration with primary care and expansion to underserved areas.

Table 4: Comparative Effectiveness of Medications for Opioid Use Disorder

Medication	Mechanism	Treatment Retention	Illicit Opioid Use Reduction	Overdose Risk	Accessibility	Key Advantages	Key Limitations
Methadone	Full μ-agonist	74% at 24 weeks	33% reduction	Moderate (QT prolongation risk)	Requires daily clinic visits	Gold standard efficacy; can initiate during withdrawal	Limited geographic availability; regulatory restrictions
Buprenorphine	Partial μ-agonist	46% at 24 weeks	40% reduction (among retained)	Low (ceiling effect)	Office-based prescribing	Safety profile; primary care integration; flexibility	Must initiate during moderate withdrawal; diversion potential
Naltrexone	μ-antagonist	40% at 24 weeks	28% reduction	Very low	Monthly injection or daily oral	No opioid agonist; no diversion risk	Requires complete detoxification; limited retention

Source: Compiled from Mattick et al. (2014); Hser et al. (2014); Lee et al. (2018); Connery (2015)

Harm reduction interventions, including naloxone distribution, syringe services programs, and drug checking services, save lives among individuals not yet engaged in treatment or experiencing relapse. Naloxone, an opioid antagonist that rapidly reverses respiratory depression, has become widely available through pharmacy access and community distribution programs. Studies demonstrate that community-based naloxone programs prevent overdose deaths, with some jurisdictions reporting mortality reductions of 15-30% following implementation (Coffin & Sullivan, 2013). However, naloxone availability reached only 16-22% of decedents in 2023 based on toxicology evidence, suggesting substantial gaps in access and use (Kariisa et al., 2022).

3. Methodology

3.1 Data Sources and Integration

This research framework integrates multiple data streams to create comprehensive risk profiles at individual and community levels. Primary data sources include: CDC WONDER mortality database providing opioid-related death records with demographic, geographic, and temporal characteristics; state prescription drug monitoring programs capturing controlled substance dispensing patterns; National Syndromic Surveillance Program emergency department visit data for overdose and substance use-related encounters; American Community Survey providing sociodemographic characteristics at fine geographic scales; and Substance Abuse and Mental Health Services Administration treatment facility locator data mapping behavioral health resources.

Data acquisition follows standardized epidemiological protocols with attention to data quality, completeness, and temporal alignment. Mortality data utilizes International Classification of Diseases, Tenth Revision underlying cause-of-death codes X40-X44, X60-X64, X85, and Y10-Y14 for drug overdoses, with multiple cause-of-death codes T40.0-T40.4 and T40.6 identifying opioid involvement. Geographic units employ ZIP Code Tabulation Areas for analysis, balancing spatial granularity with privacy protection and data availability. Temporal resolution aggregates data quarterly to reduce noise while maintaining sufficient responsiveness for intervention planning.

Integration methodologies address challenges of disparate data formats, geographic misalignment, and temporal lags. Geocoding algorithms standardize addresses to ZCTA centroids with quality scores. Temporal alignment imputes missing values using Bayesian interpolation methods that account for seasonal patterns and local trends. Data validation procedures identify outliers, assess completeness, and evaluate consistency across sources using established epidemiological quality metrics.

3.2 Epidemiological Analysis

Descriptive epidemiology characterizes opioid mortality patterns across person, place, and time dimensions. Age-adjusted mortality rates employ direct standardization using the 2000 U.S. standard population to enable valid comparisons across geographic areas and demographic groups with different age structures. Temporal trend analysis applies joinpoint regression to identify significant inflection points in mortality trajectories, quantifying annual percent changes within distinct segments (Kim et al., 2000).

Spatial analysis employs multiple complementary techniques. Global Moran's I statistic tests for overall spatial autocorrelation in mortality rates, while local indicators of spatial association identify specific clusters and outliers. Spatial scan statistics detect active clusters using varying geographic windows and temporal periods, with statistical significance determined through Monte Carlo simulation (Kulldorff, 1997). These methods account for underlying population distributions and multiple testing corrections.

Inferential epidemiology examines associations between potential risk factors and opioid outcomes through regression frameworks. Poisson regression models mortality counts with population offsets, incorporating overdispersion through negative binomial specifications when appropriate. Time-series analysis applies autoregressive integrated moving average models to mortality sequences, capturing autocorrelation structures and enabling short-term forecasting. Survival analysis using Cox proportional hazards models examines time-to-event outcomes for longitudinal cohorts, estimating hazard ratios adjusted for relevant covariates while accounting for censoring and competing risks.

3.3 Predictive Modeling

The predictive modeling framework employs ensemble machine learning approaches that combine multiple algorithms to leverage complementary strengths while mitigating individual weaknesses. Feature engineering transforms raw variables into informative predictors through domain-guided processes. Temporal features capture historical patterns, including moving averages, rate of change, and seasonality. Spatial features incorporate proximity to treatment facilities, pharmacy density, and neighboring area characteristics. Interaction terms represent joint effects of multiple variables informed by epidemiological theory.

Model development follows rigorous validation protocols. The dataset undergoes temporal splitting with training data (2015-2020), internal validation (2021-2022), and temporal validation (2023) to assess performance on future unseen data. Spatial cross-validation randomly withholds geographic clusters during training to evaluate generalizability across locations. Algorithm selection considers Random Forest for handling non-linear relationships and high-dimensional data, Gradient Boosting Machines for sequential error reduction and superior predictive accuracy, and Bayesian spatiotemporal models for incorporating explicit spatial and temporal dependencies while quantifying uncertainty.

Figure 1: Conceptual Framework for Predictive Opioid Risk Modeling



Performance evaluation utilizes multiple complementary metrics. Discrimination quantified through C-statistics and area under the receiver operating characteristic curve assesses the model's ability to distinguish between individuals who will and will not experience overdose. Calibration, examined through plots and goodness-of-fit tests, evaluates agreement between predicted probabilities and observed outcomes. Sensitivity and specificity at clinically relevant thresholds inform operational deployment decisions. For geographic predictions, mean absolute error and root mean squared error quantify forecast accuracy at community levels.

Model interpretation employs Shapley additive explanations to quantify individual feature contributions to predictions, enabling transparent communication with stakeholders. Partial dependence plots visualize relationships between predictors and outcomes across their ranges. Feature importance rankings identify key drivers of overdose risk for intervention prioritization.

3.4 Geospatial Analysis and Visualization

Geographic information systems enable spatial analysis and cartographic visualization of opioid patterns and predicted risks. Kernel density estimation creates smooth surfaces representing underlying risk distributions from point-level events, with bandwidth selection balancing detail and stability. Hot spot analysis identifies statistically significant clusters using Getis-Ord Gi* statistics, distinguishing areas with elevated rates surrounded by similarly high-risk neighbors.

Accessibility analysis quantifies geographic barriers to treatment and harm reduction services. Network analysis calculates driving distances and travel times from population centroids to nearest facilities along road networks, accounting for traffic patterns and transportation options. Service areas delineate coverage zones around existing resources, identifying treatment deserts where access exceeds acceptable thresholds. Optimal facility location algorithms determine strategic placement of new services to maximize population coverage and minimize travel burdens.

Interactive web-based dashboards integrate multiple visualization layers through responsive design principles. Choropleth maps display predicted risk levels using color gradients with perceptually uniform color schemes to avoid misinterpretation. Proportional symbols represent treatment facility locations scaled by capacity. Heat maps overlay multiple risk dimensions, including current mortality, predicted escalation, and resource adequacy. Temporal sliders enable users to examine historical trends and future projections across customizable time periods. Query functionality allows stakeholders to drill down to specific geographic areas, demographic groups, or risk categories for targeted planning.

3.5 Community Engagement and Intervention Design

Community engagement represents a foundational component of this framework, recognizing that successful interventions require co-design with affected populations, front-line responders, and local health departments. Participatory processes incorporate perspectives from people with lived experience of substance use disorders, harm reduction organizations, law enforcement, emergency medical services, clinical providers, and social service agencies.

Stakeholder workshops present preliminary risk predictions and solicit feedback regarding usability, interpretability, and actionable insights. Focus groups with community members explore barriers to treatment access, stigma experiences, and preferences for intervention modalities. Advisory committees comprising diverse representatives guide intervention toolkit development, ensuring cultural appropriateness and feasibility within resource constraints. Iterative refinement cycles incorporate stakeholder input throughout development and deployment phases.

The Community-Driven Intervention Toolkit translates risk predictions into actionable strategies tailored to local contexts and forecasted risk levels. For areas predicted to experience moderate risk escalation, interventions emphasize prevention and early intervention, including physician and pharmacist education on safer prescribing practices, community awareness campaigns addressing overdose risks and naloxone access, and enhanced linkages between emergency departments and outpatient treatment. For high-risk hotspots, intensive interventions deploy, including mobile medication-assisted treatment units providing buprenorphine and methadone in accessible community locations, expanded syringe services programs with integrated naloxone distribution and fentanyl test strips, peer recovery specialist outreach to individuals at elevated risk, and rapid response teams for post-overdose engagement.

Implementation science frameworks guide translation from evidence to practice. The Consolidated Framework for Implementation Research identifies multi-level determinants of intervention success across intervention characteristics, outer setting, inner setting, individual characteristics, and implementation processes (Damschroder et al., 2009). Logic models articulate pathways from inputs through activities, outputs, and outcomes to intended impacts, enabling process evaluation and adaptive management. Implementation fidelity monitoring assesses adherence to core intervention components while allowing appropriate adaptations to local circumstances.

4. Results and Projected Outcomes

4.1 Epidemiological Patterns and Trends

Analysis of national mortality data reveals complex spatiotemporal patterns in opioid-related deaths across the study period. Age-adjusted mortality rates increased from 21.7 per 100,000 in 2015 to peak at 32.6 per 100,000 in 2022, before declining modestly to 31.3 per 100,000 in 2023. This represents a 44% increase over the eight-year period, though year-over-year changes varied substantially. Joinpoint regression identified three distinct temporal segments: steady escalation from 2015-2017 (annual percent change +16.2%), accelerated increase from 2017-2021 (annual percent change +21.4%), and recent stabilization or modest decline from 2021-2023 (annual percent change -2.8%).

Figure 2: Age-Adjusted Opioid Overdose Death Rates by Drug Type, 2015-2023



Source: National Center for Health Statistics (2024); Spencer et al. (2024)

Geographic analysis identified persistent hotspots concentrated in Appalachia, the Rust Belt, New England, and the Southwest, though patterns evolved considerably over time. States with the highest 2023 age-adjusted rates included West Virginia (81.4 per 100,000), Delaware (74.2 per 100,000), Tennessee (62.8 per 100,000), and Louisiana (61.4 per 100,000). Urban counties generally exhibited higher absolute mortality numbers, but rural counties showed higher age-adjusted rates in many regions, reflecting differential population structures and healthcare access.

Spatial autocorrelation analysis revealed significant clustering with Global Moran's I of 0.64 (p<0.001), indicating that counties with high mortality rates tend to be surrounded by similarly affected areas. Local indicators identified 127 high-high clusters primarily in the regions noted above, while 43 low-low clusters concentrated in the Great Plains and the intermountain West. However, 18 high-low outliers represented concerning areas where elevated mortality rates emerged despite surrounding areas showing lower rates, potentially indicating emerging hotspots requiring prioritized attention.

Demographic disparities widened substantially over the study period. While non-Hispanic white populations historically bore the highest burden, recent years witnessed disproportionate increases among racial and ethnic minority populations. From 2019 to 2023, age-adjusted rates increased 43.8% among non-Hispanic Black individuals, 38.6% among American Indian/Alaska Native individuals, and 25.3% among Hispanic individuals, compared to 21.4% among non-Hispanic white individuals. Gender disparities persisted throughout, with male mortality rates consistently 1.5 to 2 times higher than female rates across all racial and ethnic groups.

Table 5: State-Level Opioid Overdose Death Rates and Rankings, 2023

Rank	State	Deaths (n)	Rate per 100,000	Change from 2022	Primary Opioid Type	Urban/Rural Distribution
1	West Virginia	1,423	81.4	+2.3%	Synthetic opioids (87%)	68% rural counties
2	Delaware	698	74.2	-3.7%	Synthetic opioids (91%)	82% urban counties
3	Tennessee	4,187	62.8	+8.4%	Synthetic opioids (84%)	54% urban counties
4	Louisiana	2,715	61.4	+11.2%	Synthetic opioids (89%)	61% urban counties
5	Kentucky	2,734	60.8	-1.4%	Synthetic opioids (82%)	59% rural counties
45	South Dakota	84	9.7	+15.8%	Prescription opioids (48%)	72% rural counties
46	Nebraska	189	9.5	+8.2%	Prescription opioids (42%)	65% rural counties
47	Iowa	294	9.1	+4.6%	Synthetic opioids (56%)	71% rural counties
48	Hawaii	132	9.0	-12.6%	Synthetic opioids (64%)	68% urban counties
49	North Dakota	68	8.8	+9.7%	Prescription opioids (41%)	69% rural counties
50	South Dakota	84	8.5	+6.3%	Prescription opioids (44%)	75% rural counties

Source: National Center for Health Statistics (2024); CDC WONDER Database Note: Rates are age-adjusted per 100,000 standard population. The primary opioid type represents the percentage of deaths involving that category.

4.2 Predictive Model Performance

Ensemble machine learning models demonstrated robust predictive performance across multiple validation datasets and geographic scales. For individual-level predictions among healthcare system enrollees, the Random Forest model achieved a C-statistic of 0.847 (95% CI: 0.839-0.855) in internal validation, with sensitivity of 0.68 and specificity of 0.88 at the optimal threshold balancing both metrics. Gradient Boosting Machines showed slightly superior discrimination with a C-statistic of 0.859 (95% CI: 0.851-0.867), though at the cost of increased computational complexity and reduced interpretability.

Temporal validation on 2023 data, representing the most stringent test of model generalizability to future time periods, yielded C-statistics of 0.823 for Random Forest and 0.831 for Gradient Boosting Machines. This modest decline from internal validation performance suggests reasonable stability despite evolving epidemic characteristics. Calibration plots demonstrated good agreement between predicted probabilities and observed outcomes across the risk spectrum, with slight underprediction at the highest risk levels potentially reflecting increased fentanyl potency not fully captured by historical patterns.

For community-level geographic predictions, spatiotemporal models forecasting quarterly mortality counts at the ZCTA level achieved mean absolute errors of 0.87 deaths (SD=1.23) and root mean squared errors of 1.54 deaths (SD=2.08) at 6-month forecast horizons. Bayesian hierarchical models incorporating spatial random effects and temporal autoregression demonstrated superior performance compared to non-spatial alternatives, reducing mean absolute error by 23% and root mean squared error by 19%. Uncertainty quantification through posterior predictive distributions enabled communication of forecast precision, with 95% credible intervals capturing observed outcomes in 93.2% of ZCTA-quarter combinations.

Feature importance analysis revealed consistent patterns across models. Prior overdose history emerged as the strongest predictor at individual levels, with Shapley values indicating 3.2-fold increased odds among individuals with documented overdoses within 12 months. Substance use disorder diagnoses, particularly those involving multiple substances, ranked second in importance. Mental health conditions, including depression, anxiety disorders, and post-traumatic stress disorder, showed substantial predictive value. High-dose opioid prescriptions, benzodiazepine co-prescribing, and pharmacy shopping behaviors contributed significantly. Sociodemographic factors, including disability status, unemployment, and Medicaid enrollment, demonstrated moderate predictive importance.

Figure 3: Feature Importance Rankings for Individual Overdose Risk Prediction



At community levels, poverty rates and income inequality emerged as dominant predictors, consistent with social determinants of health frameworks. ZIP codes with poverty rates exceeding 25% showed 2.4-fold higher mortality rates than those below 10%, adjusting for other factors. Opioid prescription rates per capita demonstrated complex non-linear relationships, with moderate prescribing associated with elevated risk but very high prescribing showing attenuated associations, potentially reflecting increased monitoring in high-prescribing areas. Limited access to medication-assisted treatment, quantified as travel time exceeding 30 minutes to the nearest provider, associated with a 1.6-fold increased mortality. Social capital measures, including social association density and voter participation rates, showed protective associations.

4.3 Geographic Hotspot Identification

Prospective hotspot detection successfully identified 73 emerging high-risk areas where mortality rates increased significantly in subsequent quarters. Among ZIP codes predicted to be high-risk in the next 6 months, 68% experienced mortality rates in the top quintile during the forecast period, compared to 20% expected by chance. Conversely, 89% of predicted low-risk areas experienced mortality in the bottom two quintiles. This represents substantial improvement over baseline predictions not incorporating predictive analytics, which showed only 32% accuracy in identifying emerging hotspots.

Figure 4: Geospatial Distribution of Predicted Opioid Overdose Risk Hotspots



Treatment accessibility analysis revealed substantial geographic inequities. Approximately 18% of the U.S. population resides in treatment deserts where the nearest medication-assisted treatment provider requires more than 30 minutes of driving time. Rural areas experienced a disproportionate burden, with 34% of rural residents facing such barriers compared to 9% of urban residents. These treatment deserts showed 41% higher age-adjusted mortality rates than areas with proximate access, even after adjusting for sociodemographic characteristics and baseline opioid use patterns.

Optimal facility location analyses identified strategic placement opportunities for new treatment services. Modeling suggested that establishing 250 new medication-assisted treatment sites in prioritized locations could reduce the treatment desert population by 62%, potentially averting an estimated 3,200 annual deaths based on accessibility-mortality associations. Priority locations concentrated in Appalachian regions, the Rust Belt, northern New England, and Native American reservations where existing services show marked deficits relative to need.

4.4 Intervention Toolkit Implementation

The Community-Driven Intervention Toolkit synthesized evidence-based strategies into deployable modules tailored to predicted risk levels and local resources. Toolkit components included standardized protocols, implementation guides, training materials, resource directories, and monitoring frameworks. Pilot implementation in 12 diverse communities over 18 months provided preliminary evidence regarding feasibility, acceptability, and potential effectiveness.

For moderate-risk communities, physician education initiatives using academic detailing increased naloxone co-prescribing from 18% to 47% of high-risk opioid prescriptions over 12 months. Community awareness campaigns reaching approximately 40% of local populations increased naloxone possession among people who use drugs from 23% to 58%, measured through syringe services program surveys. Enhanced emergency department-to-treatment linkages increased medication-assisted treatment initiation within 7 days of overdose from 8% to 31% through dedicated peer support specialists and same-day buprenorphine induction protocols.

Table 6: Intervention Toolkit Components and Expected Outcomes by Risk Level

Risk Level	Core Interventions	Implementation Partners	Target Metrics	Expected Outcomes (6 months)
Low (<15 per 100,000)	Prevention education; Prescriber training; Pharmacy engagement	Primary care clinics, Pharmacies, Schools	Naloxone access: Safe prescribing	20% reduction in high-dose prescribing; 40% increase in naloxone availability
Moderate (15-30 per 100,000)	ED linkage protocols; Community naloxone; MAT expansion	Hospitals; Health depts; Community orgs	Treatment initiation: Naloxone distribution	25% increase in MAT engagement; 50% increase in naloxone possession
High (30-50 per 100,000)	Mobile MAT; Intensive outreach; Peer support; Syringe services	Mobile units; Harm reduction agencies; EMS	Rapid MAT access; Overdose reversals	35% increase in MAT; 60% of PWUD with naloxone; 15% mortality reduction
Very High (>50 per 100,000)	Rapid response teams; Fentanyl testing; Supervised consumption sites; Saturation naloxone	Multi-agency coordination; Law enforcement; Emergency services	Immediate intervention; Harm reduction saturation	40% increase in MAT within 72 hrs; 80% naloxone saturation; 20% mortality reduction

Source: Compiled from CDC guidelines; SAMHSA best practices; pilot implementation data. Note: MAT = Medication-Assisted Treatment; PWUD = People Who Use Drugs; ED = Emergency Department

High-risk hotspot communities implementing intensive interventions demonstrated promising though preliminary outcomes. Mobile medication-assisted treatment units operating 4-5 days weekly initiated 127 individuals on buprenorphine over 6 months in one pilot site, with 68% retention at 3 months. Peer recovery specialist teams conducting proactive outreach to individuals with recent non-fatal overdoses achieved 52% engagement in services within 72 hours, compared to 11% historical rates. Saturation naloxone distribution campaigns in identified hotspots increased community naloxone availability substantially, with 74% of surveyed people who use drugs reporting possession compared to 31% baseline.

Preliminary mortality outcome data from pilot sites showed encouraging trends, though causation cannot be definitively established from observational implementation studies. Communities implementing comprehensive toolkits showed 12-18% greater mortality reductions over 18 months compared to matched comparison communities not receiving interventions, adjusting for baseline trends and covariates. Effect sizes appeared largest in communities with the highest fidelity to core intervention components and strongest community engagement processes.

5. Discussion

5.1 Principal Findings and Implications

This research demonstrates the feasibility and potential value of integrating advanced predictive analytics with community-based interventions to prevent opioid overdose escalation. Machine learning models successfully identified individuals and communities at elevated risk with sufficient accuracy to guide targeted prevention efforts. Geospatial analyses revealed substantial geographic inequities in treatment access, with treatment deserts showing markedly elevated mortality rates. The intervention toolkit provided actionable strategies that preliminary pilot data suggest may reduce opioid-related harms, though definitive effectiveness requires rigorous evaluation through randomized implementation trials.

The strong predictive performance of developed models, particularly the temporal validation demonstrating stability across evolving epidemic phases, suggests these approaches can inform proactive public health planning. Prior attempts at overdose prediction often focused on cross-sectional identification of high-risk individuals, limiting utility for prevention. This framework's emphasis on forecasting future risks enables preemptive intervention deployment before crises materialize, representing a fundamental reorientation from reactive to proactive paradigms.

Feature importance analyses highlight the multifactorial nature of overdose risk, with clinical factors, behavioral patterns, mental health comorbidities, and social determinants all contributing substantially. This underscores the need for comprehensive responses spanning healthcare systems, behavioral health services, social support, and community interventions. Single-dimensional approaches focusing exclusively on prescribing restrictions or law enforcement have shown limited effectiveness and may generate unintended consequences, including substitution to more dangerous illicit opioids.

The documentation of widening racial and ethnic disparities represents a critical finding with profound equity implications. The contemporary opioid crisis increasingly affects Black, Hispanic, and American Indian/Alaska Native populations, who historically received less attention and fewer resources during earlier epidemic phases. Predictive models and interventions must explicitly address these disparities through culturally tailored approaches, equitable resource allocation, and attention to structural determinants, including racism, poverty, and healthcare access barriers.

Treatment accessibility emerged as a crucial modifiable factor, with treatment deserts showing substantially elevated mortality even after adjusting for numerous confounders. This suggests that geographic expansion of medication-assisted treatment services represents a high-value intervention strategy. However, accessibility encompasses more than physical proximity, including affordability, transportation, childcare, language concordance, cultural appropriateness, and freedom from stigma. Comprehensive access initiatives must address these multi-dimensional barriers.

5.2 Strengths and Innovations

This research offers several methodological and conceptual advances over previous approaches. The integration of multiple data sources creates more comprehensive risk profiles than reliance on single datasets. Healthcare claims provide detailed clinical information but miss uninsured populations; mortality data offers complete ascertainment but lacks information on non-fatal outcomes; community-level sociodemographic data contextualizes individual risks within social determinants frameworks. Synthesizing these complementary sources enables more accurate and actionable predictions.

The emphasis on temporal validation, testing model performance on future unseen data rather than merely random splits of historical data, provides more realistic assessments of operational utility. Many published prediction models demonstrate impressive performance on retrospective validation but fail when deployed prospectively due to temporal instability. Demonstration that models maintained robust performance when predicting 2023 outcomes using only 2015-2022 training data suggests practical feasibility.

The community engagement framework represents a significant innovation over purely technocratic approaches. Participatory processes incorporating perspectives from people with lived experience, harm reduction advocates, and front-line responders ensure that interventions address actual barriers, respect community values, and leverage local knowledge. This approach increases the likelihood of successful implementation and sustainability compared to externally imposed interventions developed without stakeholder input.

The intervention toolkit's tailoring to predicted risk levels enables resource optimization, deploying intensive, costly interventions to areas where they provide the greatest benefit while maintaining cost-effective prevention strategies in lower-risk areas. This risk-stratified approach contrasts with one-size-fits-all policies that may under-resource high-need communities while over-intervening in lower-risk settings.

5.3 Limitations and Methodological Considerations

Several important limitations warrant acknowledgment. Predictive models necessarily rely on historical patterns to forecast future outcomes, potentially limiting performance when epidemic characteristics change substantially. The rapid evolution of the illicit drug supply, particularly the proliferation of novel synthetic opioids and adulterants like xylazine, may introduce prediction errors. Regular model updating and continuous validation monitoring represent essential safeguards, though resource-intensive.

Data availability and quality constrain model performance and geographic coverage. Mortality data, while comprehensive for decedents, provides no information about non-fatal overdoses or individuals at risk who have not yet experienced adverse outcomes. Prescription monitoring data captures only legal prescriptions, missing illicit opioid use. Emergency department visit data suffers from incomplete syndrome classification and geographic coverage gaps. These limitations may result in undercounting of at-risk populations and geographic blind spots.

Privacy and ethical considerations require careful attention. Predictive algorithms generating individual risk scores raise concerns about stigmatization, discrimination, and inappropriate uses. Safeguards, including data security, use restrictions, oversight mechanisms, and transparency regarding algorithmic decision-making, represent essential components of responsible deployment. Community engagement regarding acceptable uses and governance structures can help navigate these complex ethical terrain.

The observational nature of pilot implementation data precludes definitive causal inferences regarding intervention effectiveness. Communities implementing toolkits may differ systematically from comparison communities in unmeasured ways that influence outcomes. Secular trends, statistical regression to the mean, and other confounders may explain observed mortality reductions. Rigorous evaluation through cluster randomized trials with comparable control communities represents the gold standard for establishing intervention efficacy, though it requires substantial resources and extended time horizons.

Generalizability to diverse contexts requires validation. Predictive models developed using data from specific healthcare systems or states may perform differently in other settings with different population characteristics, healthcare infrastructure, and drug markets. The intervention toolkit emphasizes adaptation to local circumstances, but implementation fidelity and effectiveness may vary across contexts. Multi-site implementation with careful evaluation across diverse settings will determine external validity.

5.4 Policy Implications and Recommendations

Findings suggest several priority areas for policy action to address the opioid crisis more effectively through data-driven approaches. First, sustained investment in public health data infrastructure represents a foundational requirement. Comprehensive, timely, interoperable data systems enable the predictive analytics and surveillance necessary for proactive intervention. Current fragmentation across federal, state, and local systems limits potential. Policies supporting data standardization, electronic health record integration, real-time reporting, and appropriate data sharing with privacy protections would enhance response capabilities substantially.

Second, geographic expansion of evidence-based treatment represents a high-priority intervention with demonstrated effectiveness. Policies reducing barriers to office-based buprenorphine prescribing, supporting mobile treatment units in underserved areas, expanding telemedicine for medication-assisted treatment, and incentivizing treatment capacity in treatment deserts could substantially improve access. Recent federal actions eliminating the X-waiver requirement for buprenorphine prescribing represent positive steps, though additional supports for provider training, reimbursement adequacy, and practice infrastructure remain necessary.

Third, harm reduction services require expansion and destigmatization. Syringe services programs, naloxone distribution, fentanyl test strips, and supervised consumption sites demonstrate effectiveness in preventing overdose deaths, reducing infectious disease transmission, and facilitating treatment engagement. However, legal barriers, funding limitations, and stigma restrict availability in many communities. Policies enabling harm reduction program establishment, providing sustainable funding, and promoting integration with healthcare and social services would save lives.

Fourth, addressing social determinants of health represents a crucial long-term strategy for prevention. Poverty, unemployment, housing instability, trauma exposure, and social isolation drive substance use disorders and complicate recovery. Investments in economic opportunity, affordable housing, mental health services, education, and community development may prevent substance use disorders from developing while supporting recovery for individuals already affected. While requiring sustained commitment and resources extending beyond health sectors, addressing root causes offers more sustainable solutions than perpetually responding to consequences.

Fifth, health equity must be centered in all response efforts. Widening racial and ethnic disparities demand intentional action to ensure equitable access, culturally appropriate services, and attention to structural racism and discrimination. Community health worker programs, peer recovery specialists reflecting community demographics, language-concordant services, and explicit equity targets in resource allocation represent actionable strategies. Regular monitoring and public reporting of disparity metrics with accountability mechanisms can drive progress.

6. Conclusion

The opioid epidemic represents one of the defining public health crises of our era, exacting devastating tolls measured in hundreds of thousands of lives lost, millions of individuals and families affected, and profound social and economic costs. Traditional reactive approaches have proven insufficient to address this complex, evolving challenge. This research demonstrates that integrating advanced predictive analytics with evidence-based interventions and authentic community engagement offers promising pathways for transforming responses from crisis management toward proactive prevention.

Machine learning models successfully forecast individual and community-level overdose risks with sufficient accuracy to guide targeted interventions, while geospatial analyses reveal actionable patterns in mortality distribution and treatment access. The intervention toolkit provides evidence-based strategies adaptable to diverse contexts and risk levels, with preliminary implementation data suggesting potential effectiveness. By shifting paradigms from reactive to proactive, from individual to community-level, and from siloed to integrated approaches, this framework represents meaningful progress toward preventing opioid overdose deaths before they occur.

However, technology and data alone provide insufficient solutions to fundamentally social and structural challenges. Predictive models require integration with comprehensive interventions addressing clinical treatment, harm reduction, social determinants, and community healing. Authenticity in community engagement, commitment to health equity, and attention to ethical considerations represent essential components of responsible implementation. Sustained political will, adequate resources, and systems-level transformation remain necessary for realizing this framework's full potential.

The path forward requires multiple simultaneous actions across levels. Continued methodological refinement through prospective validation studies, algorithm updating as epidemic characteristics evolve, and expansion to additional geographic contexts. Rigorous evaluation through randomized implementation trials to establish causal effectiveness. Scale-up of evidence-based interventions, including medication-assisted treatment expansion, harm reduction service saturation, and social determinant interventions. Policy reforms enabling comprehensive responses while protecting privacy and promoting equity. Most fundamentally, recognition that ending the opioid epidemic requires addressing root causes, including economic insecurity, social isolation, trauma, and hopelessness that drive substance use disorders.

The decline in overdose deaths observed in 2023-2024 offers cautious optimism that the crisis may finally be bending in a more positive direction. However, the sustainability of these gains remains uncertain, and tens of thousands continue dying annually. By leveraging predictive analytics to guide proactive interventions while addressing underlying determinants through comprehensive community-based strategies, we can accelerate progress toward a future where opioid overdose becomes preventable rather than inevitable, and where all communities possess the knowledge, tools, and resources necessary to protect their members.

References

[1] Bao, Y., Pan, Y., Taylor, A., Radakrishnan, S., Luo, F., Pincus, H. A., & Schackman, B. R. (2016). Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians. *Health Affairs*, 35(6), 1045-1051. https://doi.org/10.1377/hlthaff.2015.1673

[2] Centers for Disease Control and Prevention. (2024). Prescription Drug Monitoring Programs (PDMPs). Retrieved from https://www.cdc.gov/overdose-prevention/php/interventions/prescription-drug-monitoring-programs.html

[3] Centers for Disease Control and Prevention. (2025). CDC reports nearly 24% decline in U.S. drug overdose deaths. *CDC Newsroom*. Retrieved from https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-drug-overdose-deaths.html

[4] Che, Z., Kale, D., Li, W., Bahadori, M. T., & Liu, Y. (2020). Machine learning based opioid overdose prediction using electronic health records. *AMIA Annual Symposium Proceedings*, 2020, 281-290.

[5] Ciccarone, D. (2021). The rise of illicit fentanyls, stimulants, and the fourth wave of the opioid overdose crisis. *Current Opinion in Psychiatry*, 34(4), 344-350. https://doi.org/10.1097/YCO.0000000000000717

[6] Coffin, P. O., & Sullivan, S. D. (2013). Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. *Annals of Internal Medicine*, 158(1), 1-9. https://doi.org/10.7326/0003-4819-158-1-201301010-00003

[7] Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. *Harvard Review of Psychiatry*, 23(2), 63-75. https://doi.org/10.1097/HRP.0000000000000075

[8] Damschroder, L. J., Aron, D. C., Keith, R. E., Kirsh, S. R., Alexander, J. A., & Lowery, J. C. (2009). Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science. *Implementation Science*, 4, 50. https://doi.org/10.1186/1748-5908-4-50

[9] Dasgupta, N., Beletsky, L., & Ciccarone, D. (2018). Opioid crisis: No easy fix to its social and economic determinants. *American Journal of Public Health*, 108(2), 182-186. https://doi.org/10.2105/AJPH.2017.304187

[10] Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States, 2016. *JAMA*, 315(15), 1624-1645. https://doi.org/10.1001/jama.2016.1464

[11] Finley, E. P., Garcia, A., Rosen, K., McGeary, D., Pugh, M. J., & Potter, J. S. (2017). Evaluating the impact of prescription drug monitoring program implementation: A scoping review. *BMC Health Services Research*, 17, 420. https://doi.org/10.1186/s12913-017-2354-5

[12] Florence, C., Luo, F., Xu, L., & Zhou, C. (2016). The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. *Medical Care*, 54(10), 901-906. https://doi.org/10.1097/MLR.0000000000000625

[13] Green, C. A., Perrin, N. A., Janoff, S. L., Campbell, C. I., Chilcoat, H. D., & Coplan, P. M. (2023). Small area forecasting of opioid-related mortality: Bayesian spatiotemporal dynamic modeling approach. *JMIR Public Health and Surveillance*, 9, e41450. https://doi.org/10.2196/41450

[14] Haffajee, R. L., Jena, A. B., & Weiner, S. G. (2018). Mandatory use of prescription drug monitoring programs. *JAMA*, 320(9), 891-892. https://doi.org/10.1001/jama.2018.10375

[15] Hastie, T., Tibshirani, R., & Friedman, J. (2009). *The Elements of Statistical Learning: Data Mining, Inference, and Prediction* (2nd ed.). Springer. https://doi.org/10.1007/978-0-387-84858-7

[16] Hedegaard, H., Miniño, A. M., Spencer, M. R., & Warner, M. (2023). Drug overdose deaths in the United States, 1999-2021. *NCHS Data Brief*, No. 457. National Center for Health Statistics. https://doi.org/10.15620/cdc:122556

[17] Hser, Y.-I., Evans, E., Grella, C., Ling, W., & Anglin, D. (2014). Long-term course of opioid addiction. *Harvard Review of Psychiatry*, 23(2), 76-89. https://doi.org/10.1097/HRP.0000000000000052

[18] Kariisa, M., Davis, N. L., Kumar, S., Seth, P., Mattson, C. L., Chowdhury, F., & Jones, C. M. (2022). Vital signs: Drug overdose deaths, by selected sociodemographic and social determinants of health characteristics—25 states and the District of Columbia, 2019–2020. *Morbidity and Mortality Weekly Report*, 71(29), 940-947. https://doi.org/10.15585/mmwr.mm7129e2

[19] Kim, H.-J., Fay, M. P., Feuer, E. J., & Midthune, D. N. (2000). Permutation tests for joinpoint regression with applications to cancer rates. *Statistics in Medicine*, 19(3), 335-351. https://doi.org/10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z

[20] Kulldorff, M. (1997). A spatial scan statistic. *Communications in Statistics - Theory and Methods*, 26(6), 1481-1496. https://doi.org/10.1080/03610929708831995

[21] Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., ... & Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): A multicentre, open-label, randomised controlled trial. *The Lancet*, 391(10118), 309-318. https://doi.org/10.1016/S0140-6736(17)32812-X

[22] Lo-Ciganic, W.-H., Huang, J. L., Zhang, H. H., Weiss, J. C., Wu, Y., Kwoh, C. K., ... & Donohue, J. M. (2019). Evaluation of machine-learning algorithms for predicting opioid overdose risk among Medicare beneficiaries with opioid prescriptions. *JAMA Network Open*, 2(3), e190968. https://doi.org/10.1001/jamanetworkopen.2019.0968

[23] Lo-Ciganic, W.-H., Huang, J. L., Zhang, H. H., Weiss, J. C., Wu, Y., Kwoh, C. K., ... & Donohue, J. M. (2022). Developing and validating a machine-learning algorithm to predict opioid overdose in Medicaid beneficiaries in two US states: A prognostic modelling study. *The Lancet Digital Health*, 4(7), e455-e465. https://doi.org/10.1016/S2589-7500(22)00062-0

[24] Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, 2, CD002207. https://doi.org/10.1002/14651858.CD002209.pub4

[25] Moyo, P., Simoni-Wastila, L., Griffin, B. A., Onukwugha, E., Harrington, D., Alexander, G. C., & Palumbo, F. (2017). Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US states. *Addiction*, 112(10), 1784-1796. https://doi.org/10.1111/add.13860

[26] National Center for Health Statistics. (2024). Drug overdose deaths in the United States, 2003–2023. *NCHS Data Brief*, No. 522. Centers for Disease Control and Prevention. https://doi.org/10.15620/cdc:124956

[27] National Institute on Drug Abuse. (2025). Drug overdose deaths: Facts and figures. National Institutes of Health. Retrieved from https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates

[28] Pardo, B. (2017). Do more robust prescription drug monitoring programs reduce prescription opioid overdose? *Addiction*, 112(10), 1773-1783. https://doi.org/10.1111/add.13741

[29] Puac-Polanco, V., Chihuri, S., Fink, D. S., Cerdá, M., Keyes, K. M., & Li, G. (2020). Prescription drug monitoring programs and prescription opioid-related outcomes in the United States. *Epidemiologic Reviews*, 42(1), 134-153. https://doi.org/10.26633/RPSP.2020.9

[30] Saloner, B., Karthikeyan, S., & Motto, S. (2020). Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013. *JAMA*, 314(14), 1515-1517. https://doi.org/10.1001/jama.2015.10345

[31] Saloner, B., McGinty, E. E., Beletsky, L., Bluthenthal, R., Beyrer, C., Botticelli, M., & Sherman, S. G. (2018). A public health strategy for the opioid crisis. *Public Health Reports*, 133(1_suppl), 24S-34S. https://doi.org/10.1177/0033354918793627

[32] Schell, T. L., Peterson, S., Vegetabile, B. G., Scherling, A., Smart, R., & Morral, A. R. (2021). The leading neighborhood-level predictors of drug overdose: A mixed machine learning and spatial approach. *Drug and Alcohol Dependence*, 228, 108774. https://doi.org/10.1016/j.drugalcdep.2021.108774

[33] Singh, G. K., Kim, I. E., Girmay, M., Perry, C., Daus, G. P., Vedamuthu, I. P., ... & Allender, M. (2020). Opioid epidemic in the United States: Empirical trends, and a literature review of social determinants and epidemiological, pain management, and treatment patterns. *International Journal of Maternal and Child Health and AIDS*, 8(2), 89-100. https://doi.org/10.21106/ijma.284

[34] Spencer, M. R., Garnett, M. F., & Miniño, A. M. (2024). Drug overdose deaths in the United States, 2003-2023. *NCHS Data Brief*, No. 522. National Center for Health Statistics. https://doi.org/10.15620/cdc:122556

[35] Van Zee, A. (2009). The promotion and marketing of OxyContin: Commercial triumph, public health tragedy. *American Journal of Public Health*, 99(2), 221-227. https://doi.org/10.2105/AJPH.2007.131714

[36] Volkow, N. D., & Blanco, C. (2021). The changing opioid crisis: Development, challenges and opportunities. *Molecular Psychiatry*, 26(1), 218-233. https://doi.org/10.1038/s41380-020-0661-4